Cite
Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer (mCRPC).
MLA
Fettke H., et al. Whole Blood AR-V7 and AR-V9 MRNA Expression and Treatment Response in Metastatic Castrate-Resistant Prostate Cancer (MCRPC). 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305116319&authtype=sso&custid=ns315887.
APA
Fettke H., Mant A.M., Docanto M., Martelotto L., Bukczynska P., Ng N., Parente P., Graham L.-J., Pezaro C.J., Mahon K.L., Horvath L., Todenhofer T., Azad A., Kwan E.M., & To S. (2018). Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer (mCRPC).
Chicago
Fettke H., Mant A.M., Docanto M., Martelotto L., Bukczynska P., Ng N., Parente P., et al. 2018. “Whole Blood AR-V7 and AR-V9 MRNA Expression and Treatment Response in Metastatic Castrate-Resistant Prostate Cancer (MCRPC).” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305116319&authtype=sso&custid=ns315887.